Advances of antibody drug conjugates in pancreatic cancer therapy
10.16438/j.0513-4870.2024-0403
- VernacularTitle:抗体偶联药物在胰腺癌治疗中的研究进展
- Author:
Hong-xuan LI
;
Ying WANG
;
Ju-xian WANG
- Publication Type:Research Article
- Keywords:
antibody drug conjugate;
pancreatic cancer;
target;
linker;
payload
- From:
Acta Pharmaceutica Sinica
2024;59(10):2697-2708
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is one of the most lethal malignant tumors. While the existing surgical resection and chemotherapy have failed to improve the prognosis of patients well, it is urgent to find safer and more effective therapies to meet the clinical therapeutic needs. Antibody drug conjugate (ADC) is a class of targeted antitumor agents that combines monoclonal antibodies with small molecule cytotoxic drugs via chemical linkers. ADC provided wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties which depended on their characteristics of high selectivity, high efficacy and low toxicity. In recent years, the successful application of ADC in the treatment of multiple tumors has aroused a research upsurge in ADC for pancreatic cancer. This review summarizes the structure and mechanism of ADC and the current status of ADC for pancreatic cancer in order to provide some references for the future development of ADC for pancreatic cancer.
